Clinical Trial Update: Effect of Neomycin on the Pharmacokinetics of Regorafenib [Phase 1]

View source ↗

Summary

Phase 1 study assessing how neomycin affects the pharmacokinetics of regorafenib, sponsored by Bayer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Neomycin (neomycin)
• Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED